drugset / Trial / NCT02361086
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of once-daily (QD) oral dosing of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).
Timeline
- Start
- 2014-06
- Primary completion
- 2017-12
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Seviteronel | Small molecule | — | Oral |